Compare Ryanair Holdings plc (RYAAY) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ryanair Holdings plc vs Summit Therapeutics Inc — how do they compare? Ryanair Holdings plc trades at $58.99 (market cap $29.31B), while Summit Therapeutics Inc trades at $14.57 (market cap $10.48B). The key difference: Ryanair Holdings plc is far larger — about 2.8× Summit Therapeutics Inc's market cap, and Ryanair Holdings plc pays a 1.68% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| RYAAY | SMMT | |
|---|---|---|
Market Cap | $29.31B | $10.48B |
Sector | Industrials | Health |
52-Week High | $73.82 | $29.32 |
52-Week Low | $53.24 | $13.05 |
Enterprise Value | $26.33B | $9.90B |
Dividend Yield | 1.68% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
